ABUS
Arbutus Biopharma Corp Health Care Pharmaceutical Preparations Russell 3000
$4.21Close
$810.6MMarket cap
$3.67 – $5.2252-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 37 · weaker than 63% of stocks over 12 months
- Earnings shrinking EPS −299% year on year
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
19%
1wk
up 0.2%
price change
1mo
down 11.9%
price change
12-month return
down 13%
market up 11% ·
its own down 20%
F-score
—
— Not assessed
Altman Z
6.48
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
10.6×
price / book
Earnings yield
down 4.8%
EBIT / enterprise value
Cheaper than
13%
of the market · expensive
Revenue growth
up 128%
year on year
EPS growth
down 299%
latest quarter
Sales growth
down 91%
latest quarter · -10145 pts
ROE
down 39%
return on equity
Free cash margin
down 281%
-$39.6M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-66% then +128%)
Trade setup
ATR%
3.5%
$0.15 a day · 2×ATR $3.91
RS
37 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.4×
vs 50-day average
Up/down volume
0.70
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 12, 2026
Results reaction
Aug 12, 2026-3% vs market2 sessions after results
Financials
- Net -238%
- Free cash -281%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.9M | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Operating income | -$57.8M | -$73.5M | -$65.5M | -$78.1M | -$76.3M | -$38.2M |
| Net income | -$63.7M | -$76.2M | -$69.5M | -$72.8M | -$69.9M | -$33.5M |
| Net margin | -922% | -694% | -178% | -402% | -1133% | -238% |
| Earnings per share | -$0.84 | -$0.72 | -$0.46 | -$0.44 | -$0.38 | -$0.17 |
| Free cash flow | -$51.7M | -$68.3M | -$35.9M | -$86.9M | -$65.0M | -$39.6M |
| Free cash margin | -747% | -622% | -92% | -479% | -1054% | -281% |
| Cash | $52.3M | $109.3M | $30.8M | $26.3M | $36.3M | $18.0M |
| Long-term debt | — | $0 | $0 | $0 | $0 | $0 |
| Shareholders' equity | $102.0M | $169.4M | $136.9M | $106.0M | $97.4M | $76.6M |
| Shares outstanding | 89.68m | 144.99m | 157.46m | 169.87m | 189.96m | 192.53m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 23, 2026 | Annual ↗ | Dec 31, 2025 | 82d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 27, 2025 | Annual ↗ | Dec 31, 2024 | 86d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 22, 2026 | Other events ↗ |
| Aug 21, 2026 | Other events ↗ |
| Aug 12, 2026 | Results ↗ |
| Jul 16, 2026 | Agreement ended · Director or officer change · Other events ↗ |
| May 27, 2026 | Director or officer change · Shareholder vote ↗ |
| May 13, 2026 | Results ↗ |
| Apr 15, 2026 | Other events ↗ |
| Mar 23, 2026 | Results ↗ |
| Mar 3, 2026 | Material agreement · Other events ↗ |
| Feb 20, 2026 | Other events ↗ |
| Feb 6, 2026 | Other events ↗ |
| Jan 16, 2026 | Other events ↗ |